Immunocore Holdings plc (NASDAQ:IMCR) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 167,700 shares, a decrease of 53.9% from the August 15th total of 363,500 shares. Based on an average daily trading volume, of 69,400 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.4% of the company’s stock are short sold.
Shares of NASDAQ IMCR traded up $1.68 during midday trading on Friday, reaching $34.28. 59,195 shares of the stock traded hands, compared to its average volume of 80,115. The company has a quick ratio of 5.70, a current ratio of 5.70 and a debt-to-equity ratio of 0.27. Immunocore has a one year low of $27.77 and a one year high of $61.99. The company’s 50 day moving average is $32.76 and its 200 day moving average is $37.11.
Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, August 11th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.36). As a group, equities analysts predict that Immunocore will post -4.28 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baker BROS. Advisors LP purchased a new stake in shares of Immunocore during the first quarter worth about $107,307,000. Rock Springs Capital Management LP acquired a new stake in shares of Immunocore during the first quarter worth about $97,583,000. RTW Investments LP acquired a new stake in shares of Immunocore during the first quarter worth about $50,142,000. BlackRock Inc. acquired a new stake in shares of Immunocore during the first quarter worth about $45,981,000. Finally, General Atlantic LLC acquired a new stake in shares of Immunocore during the first quarter worth about $40,442,000. Institutional investors own 35.80% of the company’s stock.
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
Featured Article: Most Volatile Stocks
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.